BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/25/2017 2:01:02 AM | Browse: 922 | Download: 951
Publication Name World Journal of Cardiology
Manuscript ID 34563
Country/Territory United States
Received
2017-05-06 15:48
Peer-Review Started
2017-05-10 10:32
To Make the First Decision
2017-05-23 00:53
Return for Revision
2017-06-12 06:23
Revised
2017-07-31 23:17
Second Decision
2017-08-11 07:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-08-16 01:12
Articles in Press
2017-08-16 01:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-09-13 06:29
Publish the Manuscript Online
2017-09-25 02:01
ISSN 1949-8462 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Systematic Reviews
Article Title Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review
Manuscript Source Invited Manuscript
All Author List Melorin Mehrzad, Rasikh Tuktamyshov and Raman Mehrzad
ORCID
Author(s) ORCID Number
Melorin Mehrzad http://orcid.org/0000-0002-7578-2720
Rasikh Tuktamyshov http://orcid.org/0000-0002-7578-2721
Raman Mehrzad http://orcid.org/0000-0002-7578-2719
Funding Agency and Grant Number
Corresponding Author Raman Mehrzad, MD, Department of Internal Medicine, Yale New Haven Hospital, Yale School of Medicine, 20 York St., New Haven, CT 06510, United States. raman.mehrzad@ynhh.org
Key Words Efficiency; Cost effectiveness; Bivalirudin; Safety
Core Tip Bivalirudin is a direct thrombin inhibitor used in clinical practice since 1990’s. It was initially introduced as an alternative medication to heparin during percutaneous coronary intervention. Early studies showed advantages of bivalirudin over heparin. We did a systematic review of the literature since 1990 and summarized all relevant trials. The majority showed better outcomes with bivalirudin. However, some trials are difficult to compare directly as protocols and patient populations differ. Bivalirudin and heparin are both acceptable options according to current ACA/AHA guidelines. Authors conclude however, that that due to bivalirudin safer bleeding profile, it should be the preferred medication for anticoagulation.
Publish Date 2017-09-25 02:01
Citation Mehrzad M, Tuktamyshov R, Mehrzad R. Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review. World J Cardiol 2017; 9(9): 761-772
URL http://www.wjgnet.com/1949-8462/full/v9/i9/761.htm
DOI http://dx.doi.org/10.4330/wjc.v9.i9.761
Full Article (PDF) WJC-9-761.pdf
Full Article (Word) WJC-9-761.doc
Manuscript File 34563-Review.docx
Answering Reviewers 34563-Answering reviewers.pdf
Audio Core Tip 34563-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 34563-Conflict-of-interest statement.pdf
Copyright License Agreement 34563-Copyright assignment.pdf
Supplementary Material 34563-Supplementary-Material-revision.docx
Peer-review Report 34563-Peer-review(s).pdf
Scientific Misconduct Check 34563-Scientific misconduct check.pdf
Scientific Editor Work List 34563-Scientific editor work list.pdf